PRESS RELEASE published on 11/14/2023 at 12:45, 2 years 4 months ago Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
PRESS RELEASE published on 10/16/2023 at 12:45, 2 years 5 months ago NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
PRESS RELEASE published on 10/12/2023 at 12:45, 2 years 5 months ago NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
PRESS RELEASE published on 08/21/2023 at 12:45, 2 years 6 months ago The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
PRESS RELEASE published on 07/11/2023 at 12:45, 2 years 8 months ago Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
PRESS RELEASE published on 07/06/2023 at 12:45, 2 years 8 months ago Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
PRESS RELEASE published on 06/29/2023 at 12:45, 2 years 8 months ago NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
PRESS RELEASE published on 05/31/2023 at 12:40, 2 years 9 months ago NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
PRESS RELEASE published on 05/16/2023 at 12:45, 2 years 10 months ago NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
PRESS RELEASE published on 04/25/2023 at 12:45, 2 years 10 months ago NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
Published on 03/16/2026 at 21:00, 10 minutes ago Amdocs Brings AI-Accelerated Application Modernization to Enterprises with NVIDIA
Published on 03/16/2026 at 19:55, 1 hour 15 minutes ago GGL Resources Corp. Updates the Status of its Earn-In Agreement on its Gold Point High-Grade Gold-Silver Project, Nevada
Published on 03/16/2026 at 18:12, 2 hours 58 minutes ago Sekur Private Data Signs Distribution Agreement In Africa
Published on 03/16/2026 at 14:00, 7 hours 10 minutes ago Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression
Published on 03/16/2026 at 13:45, 7 hours 25 minutes ago iFabric Corp Provides Strong 2025 Revenue Estimate and 2026 Outlook
Published on 03/16/2026 at 20:53, 17 minutes ago EQS-Adhoc: EPH Group AG: Extension of Alexander Lühr’s Executive Board contract; appointment of an additional Executive Board member
Published on 03/16/2026 at 19:50, 1 hour 20 minutes ago EQS-Adhoc: Softing AG approves 10% cash capital increase excluding subscription rights
Published on 03/16/2026 at 19:45, 1 hour 25 minutes ago EQS-Adhoc: Northern Data Announces FY 2025 preliminary Financial Results
Published on 03/16/2026 at 19:24, 1 hour 45 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/16/2026 at 18:45, 2 hours 25 minutes ago Cognizant Expands AI Infrastructure Capabilities with Launch of Cognizant AI Factory
Published on 03/16/2026 at 18:00, 3 hours 10 minutes ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 3 hours 12 minutes ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 3 hours 13 minutes ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026
Published on 03/16/2026 at 17:35, 3 hours 35 minutes ago Disclosure of transactions in own shares from March 9 to March 13, 2026
